BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25132394)

  • 1. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer.
    Borley J; Wilhelm-Benartzi C; Yazbek J; Williamson R; Bharwani N; Stewart V; Carson I; Hird E; McIndoe A; Farthing A; Blagden S; Ghaem-Maghami S
    BJOG; 2015 May; 122(6):843-849. PubMed ID: 25132394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
    Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Tanaka YO; Kitai S; Manabe T; Ishikawa M; Hasumi Y; Miyamoto K; Ogawa G; Satoh T; Saito T; Kasamatsu T; Nakanishi T;
    Jpn J Clin Oncol; 2021 Feb; 51(2):205-212. PubMed ID: 33556170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.
    Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Mironov S; Iyer RB; Zhou Q; Iasonos A; Paul H; Hosaka M; Aghajanian CA; Leitao MM; Gardner GJ; Abu-Rustum NR; Sonoda Y; Levine DA; Hricak H; Chi DS
    Gynecol Oncol; 2014 Sep; 134(3):455-61. PubMed ID: 25019568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
    Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
    Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of peritoneal metastases with DW-MRI, CT, and FDG PET/CT before cytoreductive surgery for advanced stage epithelial ovarian cancer.
    Mikkelsen MS; Petersen LK; Blaakaer J; Marinovskij E; Rosenkilde M; Andersen G; Bouchelouche K; Iversen LH
    Eur J Surg Oncol; 2021 Aug; 47(8):2134-2141. PubMed ID: 33812768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiological predictors of cytoreductive outcomes in women with advanced ovarian cancer.
    Kushnir CL; Spirtos NM
    BJOG; 2015 May; 122(6):850. PubMed ID: 25328032
    [No Abstract]   [Full Text] [Related]  

  • 10. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings.
    Kim HJ; Choi CH; Lee YY; Kim TJ; Lee JW; Bae DS; Kim BG
    Taiwan J Obstet Gynecol; 2014 Sep; 53(3):343-7. PubMed ID: 25286788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival.
    Avesani G; Arshad M; Lu H; Fotopoulou C; Cannone F; Melotti R; Aboagye E; Rockall A
    Radiol Med; 2020 Aug; 125(8):770-776. PubMed ID: 32239470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.
    Bristow RE; Duska LR; Lambrou NC; Fishman EK; O'Neill MJ; Trimble EL; Montz FJ
    Cancer; 2000 Oct; 89(7):1532-40. PubMed ID: 11013368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT scan does not predict optimal debulking in stage III-IV epithelial ovarian cancer: a multicentre validation study.
    MacKintosh ML; Rahim R; Rajashanker B; Swindell R; Kirmani BH; Hunt J; Brockbank E; Barton DP; Clayton RD
    J Obstet Gynaecol; 2014 Jul; 34(5):424-8. PubMed ID: 24725017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.
    Rizzuto I; Stavraka C; Chatterjee J; Borley J; Hopkins TG; Gabra H; Ghaem-Maghami S; Huson L; Blagden SP
    Int J Gynecol Cancer; 2015 Mar; 25(3):416-22. PubMed ID: 25647256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of computed tomography in the staging and predicting resectability of primary advanced ovarian carcinoma].
    Lou FL; Shi YF
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):701-5. PubMed ID: 17274380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
    Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
    Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.
    Cham S; Chen L; St Clair CM; Hou JY; Tergas AI; Melamed A; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Am J Obstet Gynecol; 2019 Jun; 220(6):571.e1-571.e8. PubMed ID: 30771346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
    Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
    Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.